PRAX · Praxis Precision Medicines, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Nov 29, 2023; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| an estimated people in the U.S. live with ET | 7M | May 2026 | — |
| average baseline TETRAS-ADL score | 31 | May 2026 | — |
| Cash and investments | 1.4B | Q1 2026 | — |
| Had seen a Physician in the last 12 Months | 65% | March/April 2026 | — |
| patients averaged years since ET diagnosis | 30 | May 2026 | — |
| Peak Sales Potential | $20B | May 2026 | — |
| reporting worsening symptoms over the past three years | 94% | May 2026 | — |
| representing ET Patients | 43,000 | March 2026 | — |
| Total Patient Responses | 1,294 | March/April 2026 | — |
| US Physicians | 2,300 | March 2026 | — |
| Writing | 1,114 | March/April 2026 | — |
| Cash, cash equivalents and marketable securities | $926.1M | FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRAX
this stock
Praxis Precision Medicines, Inc.
|
$10.50B | +27.5% | -100.0% | — | 13.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Nov 29, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRAX | +2.5% | +15.6% | +13.7% | +22.1% | +27.6% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +3.9% | +11.9% | +2.2% | +19.6% | +15.3% |